Launch of Valid Insight provides support for market access
Valid Insight’s launch aims to meet the market access challenges facing new medicines, helping life science research to translate into real-world benefits for patients and society.
Dr Steve Bradshaw, leading a team of key life science advisors and industry experts, has launched Valid Insight, a new market access consultancy created to help drug developers navigate the challenges of market access for new and innovative therapeutics.
Getting new medicines and health technologies to patients who need better treatment is becoming increasingly testing, and payers and health technology assessment bodies are demanding growing levels of evidence to show real-world value.
Valid Insight’s advisors have decades of specialist experience and business knowledge in market access, health economics, outcomes research, and product and health technology launch, pricing and reimbursement. They understand the complexity of the life science landscape and the challenges and hurdles faced by manufacturers, payers, prescribers and patients in demonstrating real-world value.
“We are investing considerable resources in developing our expertise, methods and offerings, including real-world evidence, that help our clients optimize the commercial success of their products,” said Dr Bradshaw, Valid Insight founder and managing director. “I believe that the launch of Valid Insight, and the experts we have on board, will help our clients to build the global landscape of tomorrow’s healthcare environment and deliver better outcomes to patients and society.”
The Valid Insight team will put its expertise to work to provide integrated and strategic research, analysis and value communication solutions to create insight into the market and clinical opportunity, develop evidence, communicate value and build and support centres of excellence through education and training. Its core services are based on its wealth of real in-house expertise and on primary and secondary research, including real-world evidence and research with key opinion leaders and payers.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance